Reports
Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.
Global Bleeding Disorders Therapeutics Market: By Disease Type: Hemophilia A, Hemophilia B, Von Willebrand Disease, Liver Disease, Others; By Drug Class; Regional Analysis; Historical Market and Forecast (2018-2028); Market Dynamics: SWOT Analysis, Porter’s Five Forces Analysis; Competitive Landscape; Industry Events and Developments
Global Bleeding Disorders Therapeutics Market Outlook
The global bleeding disorders therapeutics market is expected to grow at a CAGR of 7.4% during the period 2023-2028. North America and Europe are expected to be key markets.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Global Market Likely to be Driven by Advancements in Treatment Systems
Hemophilia and von Willebrand disease are common congenital bleeding disorders. Treatments have focused on replacement of the missing coagulation factor to avert or treat bleeding. Novel technologies and understanding of hemostasis have led to the development of several promising novel therapies for hemophilia and von Willebrand disease. Emergent bypass agents, such as zymogen-like factor IXa and Xa molecules are being developed; a bispecific antibody, emicizumab, has exhibited efficacy in a phase 3 trial in individuals with hemophilia A and inhibitors.
Novel Compounds Show Promise
New compounds in development target tissue factor pathway inhibitor, protein C/S system, and antithrombin to modify the hemostatic balance, and modern approaches employing modified factor VIII molecules are under tests to prevent and eradicate antibodies in hemophilia A. The first recombinant von Willebrand factor (VWF) product has been approved; it possesses VWF multimer content and does not carry factor VIII. These novel approaches may provide superior routes of administration, better dosing regimens, and enhanced efficacy for inhibition and treatment of bleeding in congenital bleeding disorders. Such developments are expected to stimulate the global bleeding disorders therapeutics market.
In von Willebrand disease (vWD), an individual either does not possess the normal levels of an important protein, or the protein does not function the way it should, therefore, the body is unable to form a stable clot. Around one percent of the population suffers from some form of the illness. The disease is inherited from one or both parents, and affects both men and women.
Hemophilia is a serious and rare X-chromosome linked congenital bleeding disorder affecting the blood's ability to clot; this means that individuals suffering from hemophilia bleed for durations than normal. Hemophilia is of two types – hemophilia A and hemophilia B. Nearly eighty percent of all people suffering from hemophilia are diagnosed with hemophilia A. The condition is also known as factor VIII (8) deficiency, because it is a lack of the clotting factor – factor VIII – that causes the condition. Almost twenty percent of people with hemophilia are diagnosed with hemophilia B or factor IX deficiency (caused by a lack of clotting factor IX).
Hemophilia and rare bleeding disorders are linked to different types of coagulation factors; therefore, different treatments are available. Prevalent therapies are dispensed by infusion therapy injected into a vein or administered subcutaneously. Replacement therapy may be administered to treat a bleeding episode in progress. It can also be carried out at home on regular intervals to help avert bleeding episodes. Receiving continuous replacement therapy is necessary for some individuals suffering from hemophilia.
Fifteen other bleeding disorders have been identified along with hemophilia A and B. These include factor VII deficiency, factor XIII deficiency, factor I (fibrinogen) deficiency, afibrinogenemia, hypofibrinogenemia, dysfibrinogenemia, factor II deficiency, factor V deficiency, factor X deficiency, factor XI deficiency (hemophilia C), Glanzmann’s thrombasthenia, Bernard-Soulier syndrome, platelet storage pool deficiency, and acquired hemophilia.
Advancing Treatments in Hemophilia and Rare Blood Disorders Likely to Boost the Market
Leading companies are combining experience in protein design with collaborations in the international scientific community to develop effective and safe treatments for individuals with hemophilia and other rare bleeding disorders. Scientists are testing innovative, long-acting and subcutaneous treatment solutions for rare blood disorders and hemophilia. Such solutions seek to reduce current treatment burden and improve clinical outcomes. These solutions would be complemented by studies on oral treatments and gene therapy. Innovative treatments being tested for bleeding disorders include gene therapy, anti-tissue factor pathway inhibitor (TFPI) or anti-TFPI, encapsulated cell therapy, and RNA interference (RNAi) therapy targeting antithrombin.
Global Bleeding Disorders Therapeutics Market Segmentation
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
By disease type, the market is classified into:
- Hemophilia A
- Hemophilia B
- Von Willebrand Disease
- Liver Disease
- Others
By drug class, the market is segmented into:
- Plasma Derived Coagulation Factor Concentrates
- Recombinant Coagulation Factor Concentrates
- Others
By region, the market is divided into:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Key Industry Players in the Global Bleeding Disorders Therapeutics Market
The report presents a detailed analysis of the following key players in the market, looking into their capacity, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
- CSL Behring
- Bayer AG
- Novo Nordisk A/S
- Biogen Inc.
- Sanofi SA
- Octapharma AG
- Others
The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2022 |
| Historical Period | 2018-2022 |
| Forecast Period | 2023-2028 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Disease Type |
|
| Breakup by Drug Class |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Snapshot
6.1 Global
6.2 Regional
7 Industry Opportunities and Challenges
8 Global Bleeding Disorders Therapeutics Market Analysis
8.1 Key Industry Highlights
8.2 Global Bleeding Disorders Therapeutics Historical Market (2018-2022)
8.3 Global Bleeding Disorders Therapeutics Market Forecast (2023-2028)
8.4 Global Bleeding Disorders Therapeutics Market by Disease Type
8.4.1 Hemophilia A
8.4.1.1 Market Share
8.4.1.2 Historical Trend (2018-2022)
8.4.1.3 Forecast Trend (2023-2028)
8.4.2 Hemophilia B
8.4.2.1 Market Share
8.4.2.2 Historical Trend (2018-2022)
8.4.2.3 Forecast Trend (2023-2028)
8.4.3 Von Willebrand Disease
8.4.3.1 Market Share
8.4.3.2 Historical Trend (2018-2022)
8.4.3.3 Forecast Trend (2023-2028)
8.4.4 Liver Disease
8.4.4.1 Market Share
8.4.4.2 Historical Trend (2018-2022)
8.4.4.3 Forecast Trend (2023-2028)
8.4.5 Others
8.5 Global Bleeding Disorders Therapeutics Market by Drug Class
8.5.1 Plasma Derived Coagulation Factor Concentrates
8.5.1.1 Market Share
8.5.1.2 Historical Trend (2018-2022)
8.5.1.3 Forecast Trend (2023-2028)
8.5.2 Recombinant Coagulation Factor Concentrates
8.5.2.1 Market Share
8.5.2.2 Historical Trend (2018-2022)
8.5.2.3 Forecast Trend (2023-2028)
8.5.3 Others
8.6 Global Bleeding Disorders Therapeutics Market by Region
8.6.1 Market Share
8.6.1.1 North America
8.6.1.2 Europe
8.6.1.3 Asia Pacific
8.6.1.4 Latin America
8.6.1.5 Middle East and Africa
9 Regional Analysis
9.1 North America
9.1.1 Historical Trend (2018-2022)
9.1.2 Forecast Trend (2023-2028)
9.1.3 Breakup by Country
9.1.3.1 United States of America
9.1.3.2 Canada
9.2 Europe
9.2.1 Historical Trend (2018-2022)
9.2.2 Forecast Trend (2023-2028)
9.2.3 Breakup by Country
9.2.3.1 United Kingdom
9.2.3.2 Germany
9.2.3.3 France
9.2.3.4 Italy
9.2.3.5 Others
9.3 Asia Pacific
9.3.1 Historical Trend (2018-2022)
9.3.2 Forecast Trend (2023-2028)
9.3.3 Breakup by Country
9.3.3.1 China
9.3.3.2 Japan
9.3.3.3 India
9.3.3.4 ASEAN
9.3.3.5 Australia
9.3.3.6 Others
9.4 Latin America
9.4.1 Historical Trend (2018-2022)
9.4.2 Forecast Trend (2023-2028)
9.4.3 Breakup by Country
9.4.3.1 Brazil
9.4.3.2 Argentina
9.4.3.3 Mexico
9.4.3.4 Others
9.5 Middle East and Africa
9.5.1 Historical Trend (2018-2022)
9.5.2 Forecast Trend (2023-2028)
9.5.3 Breakup by Country
9.5.3.1 Saudi Arabia
9.5.3.2 United Arab Emirates
9.5.3.3 Nigeria
9.5.3.4 South Africa
9.5.3.5 Others
10 Market Dynamics
10.1 SWOT Analysis
10.1.1 Strengths
10.1.2 Weaknesses
10.1.3 Opportunities
10.1.4 Threats
10.2 Porter’s Five Forces Analysis
10.2.1 Supplier’s Power
10.2.2 Buyer’s Power
10.2.3 Threat of New Entrants
10.2.4 Degree of Rivalry
10.2.5 Threat of Substitutes
10.3 Key Indicators for Demand
10.4 Key Indicators for Price
11 Competitive Landscape
11.1 Market Structure
11.2 Company Profiles
11.2.1 CSL Behring
11.2.1.1 Company Overview
11.2.1.2 Product Portfolio
11.2.1.3 Demographic Reach and Achievements
11.2.1.4 Certifications
11.2.2 Bayer AG
11.2.2.1 Company Overview
11.2.2.2 Product Portfolio
11.2.2.3 Demographic Reach and Achievements
11.2.2.4 Certifications
11.2.3 Novo Nordisk A/S
11.2.3.1 Company Overview
11.2.3.2 Product Portfolio
11.2.3.3 Demographic Reach and Achievements
11.2.3.4 Certifications
11.2.4 Biogen Inc.
11.2.4.1 Company Overview
11.2.4.2 Product Portfolio
11.2.4.3 Demographic Reach and Achievements
11.2.4.4 Certifications
11.2.5 Sanofi SA
11.2.5.1 Company Overview
11.2.5.2 Product Portfolio
11.2.5.3 Demographic Reach and Achievements
11.2.5.4 Certifications
11.2.6 Octapharma AG
11.2.6.1 Company Overview
11.2.6.2 Product Portfolio
11.2.6.3 Demographic Reach and Achievements
11.2.6.4 Certifications
11.2.7 Others
12 Industry Events and Developments
List of Figures and Tables
1. Global Bleeding Disorders Therapeutics Market: Key Industry Highlights, 2017 and 2021
2. Global Bleeding Disorders Therapeutics Historical Market: Breakup by Disease Type (USD Million), 2018-2022
3. Global Bleeding Disorders Therapeutics Market Forecast: Breakup by Disease Type (USD Million), 2023-2028
4. Global Bleeding Disorders Therapeutics Historical Market: Breakup by Drug Class (USD Million), 2018-2022
5. Global Bleeding Disorders Therapeutics Market Forecast: Breakup by Drug Class (USD Million), 2023-2028
6. Global Bleeding Disorders Therapeutics Historical Market: Breakup by Region (USD Million), 2018-2022
7. Global Bleeding Disorders Therapeutics Market Forecast: Breakup by Region (USD Million), 2023-2028
8. North America Bleeding Disorders Therapeutics Historical Market: Breakup by Country (USD Million), 2018-2022
9. North America Bleeding Disorders Therapeutics Market Forecast: Breakup by Country (USD Million), 2023-2028
10. Europe Bleeding Disorders Therapeutics Historical Market: Breakup by Country (USD Million), 2018-2022
11. Europe Bleeding Disorders Therapeutics Market Forecast: Breakup by Country (USD Million), 2023-2028
12. Asia Pacific Bleeding Disorders Therapeutics Historical Market: Breakup by Country (USD Million), 2018-2022
13. Asia Pacific Bleeding Disorders Therapeutics Market Forecast: Breakup by Country (USD Million), 2023-2028
14. Latin America Bleeding Disorders Therapeutics Historical Market: Breakup by Country (USD Million), 2018-2022
15. Latin America Bleeding Disorders Therapeutics Market Forecast: Breakup by Country (USD Million), 2023-2028
16. Middle East and Africa Bleeding Disorders Therapeutics Historical Market: Breakup by Country (USD Million), 2018-2022
17. Middle East and Africa Bleeding Disorders Therapeutics Market Forecast: Breakup by Country (USD Million), 2023-2028
18. Global Bleeding Disorders Therapeutics Market Structure
Key Questions Answered in the Report
The global bleeding disorders therapeutics market is projected to grow at a CAGR of 7.4% between 2023 and 2028.
The major drivers of the market include the R&D activities, increasing awareness, favourable reimbursement policies, and low-cost generic drugs.
Growing patient population base and increasing focus on recombinant products by pharmaceutical companies are the key industry trends propelling the market's growth.
What are the major regional markets of bleeding disorders therapeutics, according to the EMR report?
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The different types of diseases are Haemophilia A, Haemophilia B, Von Willebrand disease, and liver disease, among others.
Based on drug class, the market includes plasma derived coagulation factor concentrates and recombinant coagulation factor concentrates, among others.
The major players in the industry are CSL Behring, Bayer AG, Novo Nordisk A/S, Biogen Inc., Sanofi SA, and Octapharma AG, among others.
Analyst Review
The global bleeding disorders therapeutics market was driven by the increasing focus on recombinant products by pharmaceutical companies in the historical period. Aided by the increasing awareness and growing patient population base, the market is expected to witness further growth in the forecast period of 2023-2028, growing at a CAGR of 7.4%.
EMR's meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. The different types of diseases are Haemophilia A, Haemophilia B, Von Willebrand disease, and liver disease, among others. Based on drug class, the market includes plasma derived coagulation factor concentrates and recombinant coagulation factor concentrates, among others. The major regional markets for bleeding disorders therapeutics are North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa. The major players in the industry are CSL Behring, Bayer AG, Novo Nordisk A/S, Biogen Inc., Sanofi SA, and Octapharma AG, among others.
EMR's research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable and help them remain ahead of their competition.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$1499
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$2699-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
$3699-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$4699-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar Reports
NEWSLETTER